XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash Flows From Operating Activities:    
Net (Loss) $ (1,283,801) $ (1,702,430)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 42,618 34,710
Stock issued for services 12,000 0
Accounts receivable (536,261) 135,891
Inventory (2,100,281) (417,318)
Prepaid expenses (568,981) 129,849
Accounts Payable & accrued expenses 1,293,372 (73,661)
Income tax payable (43,824) 42,853
Net Cash Flows (Used In) Operating Activities (3,185,159) (1,850,106)
Cash Flows From Investing Activities:    
Reduction in right-of-use asset 31,066 32,934
Cash from Nora Pharma acquisition 0 (1,135)
Purchase of intangible assets (636,865) (178,395)
Purchase of equipment (62,937) 293
Net Cash Flows (Used In) Investing Activities (668,736) (146,303)
Cash Flows From Financing Activities:    
Proceeds from public offering net (common stock) 8,522,411 0
Exercise of warrants 45,000 0
Purchase of treasury stock (3,139,651) (506,822)
Lease liability (29,611) (31,477)
Net Cash Flows Provided by Financing Activities 5,398,149 (538,299)
Cash and Cash Equivalents at Beginning of Period 16,292,347 21,826,437
Net increase (decrease) in cash and cash equivalents 1,544,254 (2,534,708)
Effect of exchange rate changes on cash 141,312 2,489
Foreign currency translation adjustment (543,705) 0
Cash and Cash Equivalents at End of Period 17,434,208 19,294,218
Supplementary Disclosure of Cash Flow Information:    
Cash paid for income taxes 956,012 0
Stock issued for services $ 12,000 $ 0